Outlook Therapeutics, Inc. (OTLK)
Last updated: 2026-10-21 23:08:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Outlook Therapeutics, Inc. (OTLK) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.57, with a market capitalization of $120.02M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.16 to $2.54. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$120.02M | |
$0.55 | |
$219.20 | |
$0.16 | |
$0.52 | |
999.82K | |
12.83M | |
-- | |
$2.54 | |
$0.16 | |
-- | |
-- |
Outlook Therapeutics, Inc. (OTLK) After-Hours Stock Price
Outlook Therapeutics, Inc. (OTLK) is trading at $0.56 in after-hours trading as of 2026-10-21 23:02:00, up 6.73% ($0.04) from the regular-session close of $0.52.
After-hours trading shows how investors are pricing OTLK after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Outlook Therapeutics, Inc. (OTLK) 7-Day Stock Price Change
Over the past seven days, Outlook Therapeutics, Inc. (OTLK) moved from $0.59 to $0.57, representing a decline of 3.44% ($0.02).
The stock traded between $0.44 and $0.60 during the period. The latest price is near the upper end of the 7-day range, indicating moderate downward.
The average daily volume was 4.23 million shares, down versus the previous seven-day period, indicating lower trading activity.
OTLK 52-Week Price Position
Position in Range: 17.0%
OTLK is currently trading at $0.57, placing it 17.0% of the way from its 52-week low of $0.16 to its 52-week high of $2.54. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Outlook Therapeutics, Inc. (OTLK)?
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Outlook Therapeutics, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 17 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Outlook Therapeutics, Inc. (OTLK) Stock on MEXC
Eligible investors can buy real shares of Outlook Therapeutics, Inc. (OTLK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Outlook Therapeutics, Inc. (OTLK) stock price today?
2.Is OTLK stock going up or down today?
3.What is OTLK pre-market price?
4.What is OTLK after-hours price?
5.Is OTLK stock trading now?
6.Where does OTLK sit relative to its 52-week high and low?
7.What sector is Outlook Therapeutics, Inc. in?
8.What is Outlook Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is OTLK valued in terms of P/E ratio and EPS?
10.Does Outlook Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
OTLK Stock Calculator
Estimate the value between OTLK shares and USD.
OTLK Shares to USD
1.00 OTLK shares = 0.565 USD
Calculations are estimates based on the latest available price and are for reference only.


